[go: up one dir, main page]

DE69634905D1 - Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung - Google Patents

Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung

Info

Publication number
DE69634905D1
DE69634905D1 DE69634905T DE69634905T DE69634905D1 DE 69634905 D1 DE69634905 D1 DE 69634905D1 DE 69634905 T DE69634905 T DE 69634905T DE 69634905 T DE69634905 T DE 69634905T DE 69634905 D1 DE69634905 D1 DE 69634905D1
Authority
DE
Germany
Prior art keywords
wounds
mannose
healing
phosphate
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634905T
Other languages
English (en)
Other versions
DE69634905T2 (de
Inventor
Mark William James Ferguson
Sally Freeman
Sarah Glenys Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE69634905D1 publication Critical patent/DE69634905D1/de
Publication of DE69634905T2 publication Critical patent/DE69634905T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69634905T 1995-08-04 1996-07-31 Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung Expired - Lifetime DE69634905T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516012 1995-08-04
GBGB9516012.3A GB9516012D0 (en) 1995-08-04 1995-08-04 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69634905D1 true DE69634905D1 (de) 2005-08-04
DE69634905T2 DE69634905T2 (de) 2006-04-27

Family

ID=10778773

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69626987T Expired - Lifetime DE69626987T2 (de) 1995-08-04 1996-07-31 Pharmaceutische komposition
DE69634905T Expired - Lifetime DE69634905T2 (de) 1995-08-04 1996-07-31 Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69626987T Expired - Lifetime DE69626987T2 (de) 1995-08-04 1996-07-31 Pharmaceutische komposition

Country Status (14)

Country Link
US (1) US6140307A (de)
EP (2) EP0841931B1 (de)
JP (2) JPH11510179A (de)
AT (2) ATE298579T1 (de)
AU (1) AU719992B2 (de)
CA (1) CA2229010C (de)
DE (2) DE69626987T2 (de)
DK (2) DK1291018T3 (de)
ES (2) ES2243657T3 (de)
GB (1) GB9516012D0 (de)
HK (1) HK1053264A1 (de)
PT (2) PT841931E (de)
WO (1) WO1997005883A1 (de)
ZA (1) ZA966578B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
GB2316002B (en) * 1996-08-12 1998-09-23 British Tech Group Mannose-6-phosphate composition and its use in treating fibrotic disorders
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
AUPQ872300A0 (en) * 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
ATE440103T1 (de) * 2003-05-20 2009-09-15 Pharmaxis Pty Ltd Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten
US20080057072A1 (en) * 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
WO2008144352A1 (en) * 2007-05-17 2008-11-27 Sunny Biodiscovery, Inc. Threitol phosphates, salts thereof and methods of use
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
GB0910078D0 (en) 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916334D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
GB0916332D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Medicaments
BR112021002449A2 (pt) * 2018-08-10 2021-05-04 New York University método para melhorar a memória em um indivíduo
CN113164501B (zh) 2018-08-10 2024-08-09 纽约大学 Igf-2受体的激动剂配体治疗安格曼综合征和自闭症的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
DE68926746T2 (de) * 1988-08-19 1996-11-28 Univ Australian Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
SE8904354D0 (sv) * 1989-12-21 1989-12-21 Matti Siren A pharmaceutical composition
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
DK129293D0 (da) * 1993-11-16 1993-11-16 Carlsberg Lab Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer

Also Published As

Publication number Publication date
CA2229010C (en) 2009-06-02
CA2229010A1 (en) 1997-02-20
DK1291018T3 (da) 2005-09-12
DE69626987T2 (de) 2003-12-04
ATE298579T1 (de) 2005-07-15
PT1291018E (pt) 2005-08-31
GB9516012D0 (en) 1995-10-04
DK0841931T3 (da) 2003-04-22
EP0841931B1 (de) 2003-03-26
PT841931E (pt) 2003-06-30
JPH11510179A (ja) 1999-09-07
ATE235245T1 (de) 2003-04-15
DE69626987D1 (de) 2003-04-30
DE69634905T2 (de) 2006-04-27
EP1291018A1 (de) 2003-03-12
EP0841931A1 (de) 1998-05-20
AU6624896A (en) 1997-03-05
WO1997005883A1 (en) 1997-02-20
ES2243657T3 (es) 2005-12-01
EP1291018B1 (de) 2005-06-29
JP2008239625A (ja) 2008-10-09
HK1053264A1 (en) 2003-10-17
ES2195000T3 (es) 2003-12-01
US6140307A (en) 2000-10-31
AU719992B2 (en) 2000-05-18
ZA966578B (en) 1998-02-02

Similar Documents

Publication Publication Date Title
DE69625516D1 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69634905D1 (de) Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
DE69624925D1 (de) Verwendung von relaxin zur stimulierung der angiogenese
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE68916197D1 (de) Zusammensetzung zur in-vivo bzw. in-vitro steigerung des melaningehaltes der melanocyten und deren in-vitro verwendung.
DE68905342D1 (de) Verwendung von minoxidil zur wundheilung.
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE69930396D1 (de) Verwendung von mindestens einem derivat der 10-hydroxy-2-decenoicsäure in einer zusammensetzung zur förderung der abschuppung der haut
ES2070134T3 (es) Inhibidores de lisil oxidasa.
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung
DE59808165D1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
DE69712287D1 (de) Verwendung von Sulbutiamin zur Behandlung von psychomotorischen oder psychointellektuellen Beschwerden
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE3674921D1 (de) Behandlungsverfahren fuer aufsteigende feuchtigkeit in mauern und ausrichtung zur durchfuehrung desselben.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ATE65398T1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE3751059D1 (de) Verwendung von Corticosteroide zur Verringerung von postoperativen Schmerzen.
DE59708286D1 (de) Verwendung von wirkstoffmischungen, enthaltend phytostenole und/oder phytostenolester und potenzierungsmittel zur herstellung von hypocholesterinämischen mitteln
ATE95234T1 (de) Verfahren zur herstellung von proteinen mit fviii aktivitaet und/oder fviii derivate.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition